Monopar Therapeutics MNPR
We take great care to ensure that the data presented and summarized in this overview for Monopar Therapeutics is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MNPR
View all-
Israel Englander Millennium Management LLC | New York, Ny192KShares$119,2760.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA45.2KShares$28,0030.0% of portfolio
-
Geode Capital Management, LLC Boston, MA41.2KShares$25,5430.0% of portfolio
-
Hrt Financial LP New York, NY32.1KShares$19,9100.0% of portfolio
-
Gerber, LLC Columbus, OH28KShares$17,3630.02% of portfolio
-
Virtu Financial LLC New York, NY23.8KShares$14,7720.0% of portfolio
-
Rappaport Reiches Capital Management, LLC Skokie`, IL10.7KShares$6,6300.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY7.86KShares$4,8700.0% of portfolio
-
New Edge Advisors, LLC New Orleans, LA3KShares$1,8600.0% of portfolio
-
Ubs Group Ag2.57KShares$1,5920.0% of portfolio
Latest Institutional Activity in MNPR
Top Purchases
Top Sells
About MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Insider Transactions at MNPR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
20,508
+9.92%
|
$0
$0.74 P/Share
|
|
Jun 18
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+6.76%
|
$0
$0.86 P/Share
|
|
Jun 17
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+7.25%
|
$0
$0.9 P/Share
|
|
Jun 14
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+7.81%
|
$0
$0.93 P/Share
|
|
Jun 13
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+8.47%
|
$0
$0.91 P/Share
|
|
Jun 04
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+9.26%
|
$0
$0.78 P/Share
|
|
Jun 03
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+10.2%
|
$0
$0.76 P/Share
|
|
May 31
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+11.36%
|
$0
$0.64 P/Share
|
|
May 30
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+12.82%
|
$0
$0.64 P/Share
|
|
May 29
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+14.7%
|
$0
$0.64 P/Share
|
|
May 28
2024
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
84,000
+25.14%
|
-
|
|
Mar 31
2024
|
Andrew Cittadine Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,098
-5.1%
|
$0
$0.68 P/Share
|
|
Mar 31
2024
|
Andrew Cittadine Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,952
+12.85%
|
-
|
|
Mar 31
2024
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,172
-4.14%
|
$0
$0.68 P/Share
|
|
Mar 31
2024
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,474
+12.37%
|
-
|
|
Mar 31
2024
|
Kim R Tsuchimoto Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,082
-7.48%
|
$0
$0.68 P/Share
|
|
Mar 31
2024
|
Kim R Tsuchimoto Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,956
+15.43%
|
-
|
|
Jan 01
2024
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,327
-1.54%
|
$0
$0.34 P/Share
|
|
Jan 01
2024
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,724
+4.26%
|
-
|
|
Jan 01
2024
|
Kim R Tsuchimoto Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
505
-1.12%
|
$0
$0.34 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 232K shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 84K shares |
| Open market or private purchase | 129K shares |
| Payment of exercise price or tax liability | 65.5K shares |
|---|